336 related articles for article (PubMed ID: 11244507)
21. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of the tumor suppressor gene Smad4/DPC4 induces p21waf1 expression and growth inhibition in human carcinoma cells.
Hunt KK; Fleming JB; Abramian A; Zhang L; Evans DB; Chiao PJ
Cancer Res; 1998 Dec; 58(24):5656-61. PubMed ID: 9865717
[TBL] [Abstract][Full Text] [Related]
23. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
Báez A; Cantor A; Fonseca S; Marcos-Martinez M; Mathews LA; Muro-Cacho CA; Muñoz-Antonia T
Clin Cancer Res; 2005 May; 11(9):3191-7. PubMed ID: 15867212
[TBL] [Abstract][Full Text] [Related]
24. Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism.
Schiller M; Verrecchia F; Mauviel A
Oncogene; 2003 Dec; 22(55):8881-90. PubMed ID: 14654784
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
26. Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1.
Jinnin M; Ihn H; Asano Y; Yamane K; Trojanowska M; Tamaki K
Oncogene; 2004 Mar; 23(9):1656-67. PubMed ID: 15001984
[TBL] [Abstract][Full Text] [Related]
27. A novel dominant negative Smad2 mutation in a TGFbeta resistant human carcinoma cell line.
Tsang KJ; Tsang D; Brown TN; Crowe DL
Anticancer Res; 2002; 22(1A):13-9. PubMed ID: 12017275
[TBL] [Abstract][Full Text] [Related]
28. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.
Suh N; Roberts AB; Birkey Reffey S; Miyazono K; Itoh S; ten Dijke P; Heiss EH; Place AE; Risingsong R; Williams CR; Honda T; Gribble GW; Sporn MB
Cancer Res; 2003 Mar; 63(6):1371-6. PubMed ID: 12649201
[TBL] [Abstract][Full Text] [Related]
29. A novel SMAD4 gene mutation in seminoma germ cell tumors.
Bouras M; Tabone E; Bertholon J; Sommer P; Bouvier R; Droz JP; Benahmed M
Cancer Res; 2000 Feb; 60(4):922-8. PubMed ID: 10706106
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation.
Cheng PL; Chang MH; Chao CH; Lee YH
Oncogene; 2004 Oct; 23(47):7821-38. PubMed ID: 15334054
[TBL] [Abstract][Full Text] [Related]
31. Loss of Smad3 in acute T-cell lymphoblastic leukemia.
Wolfraim LA; Fernandez TM; Mamura M; Fuller WL; Kumar R; Cole DE; Byfield S; Felici A; Flanders KC; Walz TM; Roberts AB; Aplan PD; Balis FM; Letterio JJ
N Engl J Med; 2004 Aug; 351(6):552-9. PubMed ID: 15295048
[TBL] [Abstract][Full Text] [Related]
32. Smad2 and Smad4 gene mutations in hepatocellular carcinoma.
Yakicier MC; Irmak MB; Romano A; Kew M; Ozturk M
Oncogene; 1999 Aug; 18(34):4879-83. PubMed ID: 10490821
[TBL] [Abstract][Full Text] [Related]
33. Dpc4 transcriptional activation and dysfunction in cancer cells.
Dai JL; Turnacioglu KK; Schutte M; Sugar AY; Kern SE
Cancer Res; 1998 Oct; 58(20):4592-7. PubMed ID: 9788608
[TBL] [Abstract][Full Text] [Related]
34. Preserved Smad4 expression in the transforming growth factor beta signaling pathway is a favorable prognostic factor in patients with advanced gastric cancer.
Xiangming C; Natsugoe S; Takao S; Hokita S; Ishigami S; Tanabe G; Baba M; Kuroshima K; Aikou T
Clin Cancer Res; 2001 Feb; 7(2):277-82. PubMed ID: 11234879
[TBL] [Abstract][Full Text] [Related]
35. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer.
Kleeff J; Maruyama H; Friess H; Büchler MW; Falb D; Korc M
Biochem Biophys Res Commun; 1999 Feb; 255(2):268-73. PubMed ID: 10049697
[TBL] [Abstract][Full Text] [Related]
36. Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation.
Yang L; Wang N; Tang Y; Cao X; Wan M
Hum Mutat; 2006 Sep; 27(9):897-905. PubMed ID: 16865698
[TBL] [Abstract][Full Text] [Related]
37. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.
Schwarte-Waldhoff I; Klein S; Blass-Kampmann S; Hintelmann A; Eilert C; Dreschers S; Kalthoff H; Hahn SA; Schmiegel W
Oncogene; 1999 May; 18(20):3152-8. PubMed ID: 10340387
[TBL] [Abstract][Full Text] [Related]
38. Restoration of transforming growth factor Beta signaling by functional expression of smad4 induces anoikis.
Ramachandra M; Atencio I; Rahman A; Vaillancourt M; Zou A; Avanzini J; Wills K; Bookstein R; Shabram P
Cancer Res; 2002 Nov; 62(21):6045-51. PubMed ID: 12414627
[TBL] [Abstract][Full Text] [Related]
39. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
Kurokawa M; Mitani K; Irie K; Matsuyama T; Takahashi T; Chiba S; Yazaki Y; Matsumoto K; Hirai H
Nature; 1998 Jul; 394(6688):92-6. PubMed ID: 9665135
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein.
Yingling JM; Datto MB; Wong C; Frederick JP; Liberati NT; Wang XF
Mol Cell Biol; 1997 Dec; 17(12):7019-28. PubMed ID: 9372933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
